<DOC>
	<DOCNO>NCT02207556</DOCNO>
	<brief_summary>In study investigator want find addition antibiotic , doxycycline , standard anti-amyloid therapy people amyloidosis . The investigator want find whether doxycycline improve response standard anti-amyloid therapy whether cause problem ( side effect ) .</brief_summary>
	<brief_title>Oral Doxycycline Administered Adjunct Plasma Cell Directed Therapy Light Chain Amyloidosis</brief_title>
	<detailed_description>Organ response anti-plasma cell therapy AL amyloidosis tend lags behind hematologic response chemotherapy may clear pre-formed organ amyloid . Doxycycline show inhibitory effect amyloid fibril formation well de-fibrillogenic effect show beneficial vitro , murine model preclinical study . The investigator prospectively evaluate safety efficacy doxycycline AL amyloidosis patient use conjunction anti-plasma cell chemotherapy .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1 . Patients biopsy proven AL amyloidosis . 2 . Patients â‰¥ 18 year age eligible . 3 . Patient must provide informed consent . 4 . All patient must measurable amyloid organ involvement vital organ ( eg . heart , liver , kidney ) . Localized amyloidosis also eligible long amyloid involvement radiologically measurable . 5 . A negative pregnancy test require woman child bear potential . Breast feeding permit . 6 . Patients previously take doxycyline eligible long contraindication stay doxycycline 100 mg BID 1 year opinion treat physician . 7 . Creatinine clearance &gt; 25 ml/min . 1 . Patients severe malabsorption syndrome preclude absorption oral agent exclude . 2 . Known intolerance allergic reaction doxycycline . 3 . Previous chemotherapy AL amyloidosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AL amyloidosis</keyword>
	<keyword>amyloidosis</keyword>
	<keyword>light chain amyloidosis</keyword>
</DOC>